ERGO Stock Overview
Engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Entia Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.93% |
| 5 Year Change | -98.89% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ERGO | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.4% |
| 1Y | n/a | -28.7% | 22.9% |
Return vs Industry: Insufficient data to determine how ERGO performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how ERGO performed against the US Market.
Price Volatility
| ERGO volatility | |
|---|---|
| ERGO Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ERGO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ERGO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Timothy Timmins | www.entiabio.com |
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company’s portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant.
Entia Biosciences, Inc. Fundamentals Summary
| ERGO fundamental statistics | |
|---|---|
| Market cap | US$3.41k |
| Earnings (TTM) | -US$1.40m |
| Revenue (TTM) | US$265.47k |
0.0x
P/S Ratio0.0x
P/E RatioIs ERGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERGO income statement (TTM) | |
|---|---|
| Revenue | US$265.47k |
| Cost of Revenue | US$91.50k |
| Gross Profit | US$173.97k |
| Other Expenses | US$1.57m |
| Earnings | -US$1.40m |
Last Reported Earnings
Dec 31, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ERGO perform over the long term?
See historical performance and comparison